In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Moderna's current price at $254.19 vastly exceeds the PERT-weighted fair value of $28.20, indicating significant overvaluation with an implied downside near 89%. Valuation methods, especially DCF analysis, suggest negligible intrinsic value, while financial health scores highlight strong liquidity but zero profitability and efficiency. Monte Carlo analysis shows no downside scenarios below the current price, signaling high risk despite liquidity strength.